Categories: Gastrointestinal diseases, Immune diseases, Infectious diseases

Aliases & Classifications for Gastritis

MalaCards integrated aliases for Gastritis:

Name: Gastritis 12 29 55 6 44 15 63 17 72
Acute Gastric Mucosal Erosion 12 72
Erosive Gastropathy 12 72
Erosive Gastritis 12 72
Idiopathic Erosive/hemorrhagic Gastritis 72
Gastritis Erosive 55


External Ids:

Disease Ontology 12 DOID:4029
MeSH 44 D005756
NCIt 50 C26780
SNOMED-CT 68 4556007
ICD10 33 K29.7
UMLS 72 C0017152 C0267112 C2243088 more

Summaries for Gastritis

PubMed Health : 63 About gastritis: The membranes lining the stomach wall protect it from acid and germs. If this protective lining is irritated or damaged, it can become inflamed. Long-lasting inflammations can further damage the stomach lining and lead to stomach (gastric) ulcers. Inflammation of the stomach lining is called gastritis. It is usually caused by certain bacteria or anti-inflammatory medication. There are two kinds of gastritis: acute and chronic. Acute gastritis is typically accompanied by very noticeable stomach and bowel problems that usually go away again on their own after a few days. Chronic gastritis, on the other hand, sometimes goes unnoticed. People may only realize they have it when complications like stomach ulcers arise.

MalaCards based summary : Gastritis, also known as acute gastric mucosal erosion, is related to autoimmune atrophic gastritis and alcoholic gastritis, and has symptoms including dyspepsia and gastric irritation. An important gene associated with Gastritis is PGC (Progastricsin), and among its related pathways/superpathways are Innate Immune System and Toll Comparative Pathway. The drugs Mirtazapine and Ursodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and t cells.

Disease Ontology : 12 A stomach disease that is an inflammation of the lining of the stomach.

Wikipedia : 75 Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a... more...

Related Diseases for Gastritis

Diseases in the Gastritis family:

Autoimmune Gastritis Viral Gastritis
Bacterial Gastritis

Diseases related to Gastritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 658)
# Related Disease Score Top Affiliating Genes
1 autoimmune atrophic gastritis 34.9 GAST CHGA
2 alcoholic gastritis 34.8 PTGS2 IL1B
3 atrophic gastritis 32.8 S100A8 PGC PGA5 PGA3 IL1RN IL1B
4 helicobacter pylori infection 32.7 S100A8 IL1B GAST CXCL8 CXCL1
5 stomach disease 31.3 TFF2 S100A8 PTGS2 IL1B HRH2 GHRL
6 esophagitis 31.3 PTGS2 IL1B HRH2 CXCL8
7 peptic esophagitis 31.3 IL1B HRH2 CXCL8
8 dyspepsia 31.2 PTGS2 PGC HRH2 GHRL CXCL8
9 colitis 31.2 PTGS2 NOS2 IL1B CXCL8
10 gastric cancer 31.2 TFF2 S100A8 PTGS2 IL1RN IL1B GAST
11 duodenal ulcer 31.2 S100A8 IL1RN IL1B HRH2 GAST CXCL8
12 gastric ulcer 31.0 PTGS2 IL1RN IL1B HRH2 GAST CXCL8
13 crohn's colitis 31.0 NOS2 IL1B CXCL8
14 zollinger-ellison syndrome 31.0 HRH2 GAST CHGA
15 gastric neuroendocrine neoplasm 30.8 GAST CHGA
16 gastric adenocarcinoma 30.7 S100A8 PTGS2 IL1RN IL1B GAST CXCL8
17 proteasome-associated autoinflammatory syndrome 1 30.7 PTGS2 NOS2 IL1RN IL1B CXCL8
18 peptic ulcer disease 30.6 S100A8 PTGS2 IL1RN IL1B HRH2 GHRL
19 pharyngitis 30.6 PTGS2 IL1B CXCL8
20 gastrointestinal system disease 30.5 S100A8 PTGS2 IL1B GHRL GAST CXCL8
21 gingivitis 30.5 IL1B DEFB4A CXCL8
22 active peptic ulcer disease 30.4 PTGS2 HRH2
23 gastroesophageal reflux 30.4 PTGS2 IL1B HRH2 GHRL GAST CXCL8
24 pouchitis 30.4 IL1RN CXCL8
25 bacterial infectious disease 30.3 IL1B DEFB4A DEFB1 CXCL8
26 chagas disease 30.2 NOS2 IL1B CXCL8
27 esophageal disease 30.2 PTGS2 HRH2 GAST
28 arthritis 30.2 PTGS2 IL1RN IL1B CXCL8
29 tonsillitis 30.1 IL1B DEFB4A DEFB1 CXCL8
30 intestinal disease 29.9 PTGS2 IL1B GHRL DEFB4A CXCL8
31 large intestine cancer 29.9 PTGS2 IL1B GAST CXCL8
32 peptic ulcer perforation 29.7 S100A8 PTGS2 HRH2 GAST
33 rheumatoid arthritis 29.7 PTGS2 IL1RN IL1B CXCL8 CXCL1
34 pneumonia 29.4 IL1B CXCL8 CXCL1
35 cystic fibrosis 29.4 S100A8 DEFB4A DEFB1 CXCL8
36 collagenous gastritis 12.6
37 gastritis, familial giant hypertrophic 12.6
38 bacterial gastritis 12.5
39 herpetic gastritis 12.5
40 granulomatous gastritis 12.5
41 chronic erosive gastritis 12.4
42 lymphocytic gastritis 12.4
43 eosinophilic gastritis 12.3
44 autoimmune gastritis 12.3
45 necrotizing gastritis 12.3
46 cystic fibrosis with helicobacter pylori gastritis, megaloblastic anemia, and mental retardation 12.3
47 pediatric collagenous gastritis 12.3
48 viral gastritis 12.3
49 fungal gastritis 12.2
50 eosinophilic enteropathy 12.0

Graphical network of the top 20 diseases related to Gastritis:

Diseases related to Gastritis

Symptoms & Phenotypes for Gastritis

UMLS symptoms related to Gastritis:

dyspepsia, gastric irritation

Drugs & Therapeutics for Gastritis

PubMed Health treatment related to Gastritis: 63

If you notice that stress, alcohol or nicotine affect your symptoms, you can try to change your diet, stop drinking alcohol, quit smoking and reduce stress in everyday life. If these lifestyle changes are not enough to relieve the symptoms, medication is considered. Gastritis not caused by Helicobacter pylori is usually treated with medication to lower acid levels. Depending on the type and severity of the symptoms, the following drugs can be used: Proton pump inhibitors (PPIs) like omeprazole or pantoprazole reduce the production of stomach acid.H2 blockers such as ranitidine and famotidine also reduce acid production.Antacids like aluminium hydroxide or magnesium hydroxide neutralize the acid already in your stomach. If the gastritis is caused by a Helicobacter infection and is accompanied by noticeable symptoms, it will be treated using a combination of two or three antibiotics and an acid-lowering proton pump inhibitor. If the gastritis is caused by an NSAID painkiller, it is a good idea to consult your doctor about switching to a different painkiller or combining it with an acid-lowering medication. Should an NSAID have to be taken regularly, it is possible to take it along with acid-lowering medication from the start, as a precaution.

Drugs for Gastritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
Sucralfate Approved Phase 4 54182-58-0
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
Ethanol Approved Phase 4 64-17-5 702
Wormwood Approved, Experimental Phase 4
Clarithromycin Approved Phase 4 81103-11-9 84029
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
Licorice Approved Phase 4
Titanium dioxide Approved Phase 4 13463-67-7
Sodium citrate Approved, Investigational Phase 4 68-04-2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
Ofloxacin Approved Phase 4 82419-36-1 4583
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
Pantoprazole Approved Phase 4 102625-70-7 4679
Ranitidine Approved Phase 4 66357-35-5, 66357-59-3 3001055
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
38 Rebamipide Investigational Phase 4 90098-04-7
Cobalamin Experimental Phase 4 13408-78-1 6857388
40 Mosapride Investigational Phase 4 112885-41-3
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
Sulforaphane Investigational Phase 4 4478-93-7, 142825-10-3 5350
43 Tranquilizing Agents Phase 4
44 Anti-Anxiety Agents Phase 4
45 Cytochrome P-450 CYP3A Inhibitors Phase 4
46 Serotonin Antagonists Phase 4
47 Serotonin 5-HT2 Receptor Antagonists Phase 4
48 Adrenergic alpha-Antagonists Phase 4
49 Adrenergic alpha-2 Receptor Antagonists Phase 4
50 Serotonin 5-HT3 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 320)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
2 Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss Unknown status NCT01240096 Phase 4 Mirtazapine
3 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
4 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
5 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
6 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
7 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
8 Effectiveness of Low Level Laser at the Auriculotherapy Points, in Reducing Postoperative Pain in Third Molar Surgery Unknown status NCT02657174 Phase 4
9 Therapeutic Effect of Ursodeoxycholic Acid on Duodenal Permeability and Meal Related Sensory Motor Function in Functional Dyspepsia Patients Unknown status NCT03004118 Phase 4 Placebo Oral Tablet;Ursochol oral tablet
10 A Prospective, Randomized, Double-blind, Double-dummy, Sucralfate Controlled, Multicenter Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis Completed NCT01284647 Phase 4 Teprenone capsule and placebo of sucralfate;Sucralfate and placebo of teprenone
11 A Multiple-center, Self-controlled Open Study to Evaluate Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer Completed NCT01190657 Phase 4 Selbex;Selbex
12 A Phase IV Study to Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis Completed NCT01474044 Phase 4 Gastropylor Complex Capsules
13 Clinical Effect of Rebamipide on Chronic Gastritis Completed NCT02393430 Phase 4 Rebamipide
14 A Phase 4, Multicenter, Randomized, Open, Active Drug Comparative Trial to Evaluated the Efficacy and Safety of EUPASIDIN-S Tab. in Gastritis Patients Completed NCT02356679 Phase 4 Eupasidin-s Tab;Stillen Tab.
15 A Multicenter, Active-controlled, Randomized, Double-blind Paralleled-group Clinical Trial to Evaluate the Efficacy of 4-week Treatment With Stillen Tab. in Patients With Acute or Chronic Gastritis Completed NCT01817556 Phase 4 Stillen Tab.;Mucosta Tab.
16 A Multicenter, Randomized, Open-label Phase IV Study Exploring Symptom Control Rate in Co-diagnosed NERD and Chronic Gastritis Patients Treated With 8 Weeks Esomeprazole Treatment Regimen and 2 Weeks Esomeprazole Treatment Regimen Completed NCT01119768 Phase 4 Esomeprazole;Esomeprazole
17 A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease Completed NCT00534443 Phase 4
18 Double-blind Trial With Rikkunshito Versus Placebo on Efficacy and Safety in Patients With Functional Dyspepsia: Multi-center Study (DREAM Study) Completed NCT02037776 Phase 4 Rikkunshito;Rikkunshito placebo
19 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
20 Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy Completed NCT01792700 Phase 4 esomeprazole;tripotassium dicitrate bismuthate;metronidazole;tetracycline;moxifloxacin;amoxicillin
21 Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori Completed NCT02873065 Phase 4 Ilaprazole;Esoprazole
22 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
23 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
24 A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome Completed NCT00663897 Phase 4 lansoprazole;mosapride
25 Efficacy of Banhasasim-tang on Functional Dyspepsia : a Randomized, Double Blind, Placebo Controlled, Two-center Trial Completed NCT00987805 Phase 4
26 Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
27 Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase Ⅳ Trail Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
28 Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
29 An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
30 Evaluation of Patients With Non-cardiac Chest Pain Using PillCam Eso - a Wireless Imaging Capsule of the Esophagus. Completed NCT00476398 Phase 4
31 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
32 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02483715 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
33 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
34 Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication - A Prospective, Comparative Study Completed NCT01163435 Phase 4 high dose dual therapy;sequential therapy;clarithromycin-based triple therapy;levofloxacin-based triple therapy
35 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
36 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
37 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
38 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
39 Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia Completed NCT00951431 Phase 4 Esomeprazole;Placebo
40 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
41 A Comparative Evaluation of Diclofenac Sodium Transdermal Patch, Oral Diclofenac Sodium With Intramuscular Injections of Diclofenac Sodium in Patients Suffering From Oral Pain: A Randomized Control Trial Completed NCT03221946 Phase 4 Diclofenac Sodium;Diclofenac sodium;Diclofenac
42 Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers Completed NCT00472550 Phase 4 esomeprazole 20 mg
43 Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Recruiting NCT02175186 Phase 4 ALBIS;Placebo
44 Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets Recruiting NCT03857425 Phase 4 Clostridum Butyricum Capsule;Bacillus Coagulans Tablets;Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets
45 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy
46 A Randomized Controlled Trial of Triple Therapy With Conventional Proton Pump Inhibitor vs Triple Therapy With Vonoprazan as First Line Therapy for Helicobacter Pylori Gastritis Recruiting NCT03908619 Phase 4 Omeprazole 20mg;Esomeprazole 20mg;Rabeprazole Sodium 20mg;Vonoprazan
47 A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children Recruiting NCT03299725 Phase 4 colloidal bismuth sub-citrate
48 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study Recruiting NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
49 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy Recruiting NCT03609892 Phase 4 Berberine;Amoxicillin;Esomeprazole;Bismuth;Tetracycline;Furazolidone;Esomeprazole;Bismuth
50 Efficacies of High-dose Dual Therapy With or Without Bismuth Versus Amoxicillin-metronidazole Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication - A Prospective, Randomized, Comparative Study Recruiting NCT03897244 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate);Amoxicillin-Metronidazole Bismuth quadruple therapy

Search NIH Clinical Center for Gastritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Cat's Claw preparation

Cochrane evidence based reviews: gastritis

Genetic Tests for Gastritis

Genetic tests related to Gastritis:

# Genetic test Affiliating Genes
1 Gastritis 29

Anatomical Context for Gastritis

MalaCards organs/tissues related to Gastritis:

Testes, Colon, T Cells, Liver, Thyroid, B Cells, Neutrophil

Publications for Gastritis

Articles related to Gastritis:

(show top 50) (show all 20944)
# Title Authors PMID Year
Defensin-mRNA expression in the upper gastrointestinal tract is modulated in children with celiac disease and Helicobacter pylori-positive gastritis. 9 38
20400909 2010
Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. 9 38
20026064 2010
Prevalence of Helicobacter pylori vacA, cagA, iceA and oipA genotypes in Tunisian patients. 9 38
20302630 2010
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. 9 38
19711347 2010
TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. 9 38
20332463 2010
In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori-infected children. 9 38
20038850 2010
Interleukin 1 beta (IL1B) gene polymorphisms are not associated with gastric carcinogenesis in Germany. 9 38
20332462 2010
[Quantification of cyclooxygenase-2 methylation in gastric mucosa by denaturing high performance liquid chromatography assay]. 9 38
20388365 2010
Gastrin induces the interaction between human mononuclear leukocytes and endothelial cells through the endothelial expression of P-selectin and VCAM-1. 9 38
19812370 2009
Gastric ghrelin in relation to gender, stomach topography and Helicobacter pylori in dyspeptic patients. 9 38
19916170 2009
homB status of Helicobacter pylori as a novel marker to distinguish gastric cancer from duodenal ulcer. 9 38
19710266 2009
RANTES promoter genotype and gastric cancer risk in a Japanese population. 9 38
19846984 2009
Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma. 9 38
19385974 2009
Transforming growth factor-B1 and matrix metalloproteinase-7 promoter variants induce risk for Helicobacter pylori-associated gastric precancerous lesions. 9 38
19317620 2009
Remnant gastritis should be evaluated histologically rather than endoscopically. 9 38
19621726 2009
A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. 9 38
19262506 2009
Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. 9 38
19399945 2009
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 9 38
18612816 2009
Gender difference of circulating ghrelin and leptin concentrations in chronic Helicobacter pylori infection. 9 38
19191897 2009
[Dynamics of pro-and anti-inflammatory cytokines at patients with combination of chronic opisthorchiasis with Helicobacter pylori-associated gastritis]. 9 38
19551959 2009
Cross-talk between inducible nitric oxide synthase and cyclooxygenase in Helicobacter-pylori-induced gastritis. 9 38
19797925 2009
The relationship between virulence factors of Helicobacter pylori and severity of gastritis in infected patients. 9 38
18465229 2009
Iron deficiency, Helicobacter infection and gastritis. 9 38
19907146 2009
Decreased TFF2 expression in the gastric antrum in patients infected with CagA-positive Helicobacter pylori. 9 38
19344006 2009
Prevalence of Helicobacter pylori pathogenicity-associated cagA and vacA genotypes among Pakistani dyspeptic patients. 9 38
19040660 2009
Role of cyclooxygenase-2 functional gene polymorphisms in Helicobacter pylori induced gastritis and gastric atrophy. 9 38
18825488 2009
Potential role of human beta-defensin 1 in Helicobacter pylori-induced gastritis. 9 38
18991164 2009
Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. 9 38
18985541 2009
Bile acid induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells. 9 38
18775915 2008
The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis. 9 38
18571838 2008
Presence of poorly differentiated component correlated with submucosal invasion in the early diffuse-type gastric cancer. 9 38
19260519 2008
cagA, vacA, and iceA genotypes of Helicobacter pylori in Korean children. 9 38
19261108 2008
Helicobacter pylori infection induces a reversible expression of the CDX2 transcription factor protein in human gastric epithelium. 9 38
19086163 2008
vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. 9 38
18653971 2008
Serum gastrin concentration and changes in G and D cell densities in gastric antrum in children with chronic gastritis. 9 38
17573842 2008
Four modes of adhesion are used during Helicobacter pylori binding to human mucins in the oral and gastric niches. 9 38
18321298 2008
Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. 9 38
17934843 2008
The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. 9 38
18321304 2008
IL-4 -588C>T polymorphism and IL-4 receptor alpha [Ex5+14A>G; Ex11+828A>G] haplotype concur in selecting H. pylori cagA subtype infections. 9 38
18179773 2008
Expression of 8-hydroxydeoxyguanosine in the gastric remnant after distal gastrectomy. 9 38
18613397 2008
Long-term effects of Helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children. 9 38
18299465 2008
T-251A polymorphism of IL-8 relating to the development of histological gastritis and G-308A polymorphism of TNF-alpha relating to the development of macroscopic erosion. 9 38
18301299 2008
Autoimmune gastritis in type 1 diabetes: a clinically oriented review. 9 38
18029461 2008
Is interleukin-1 genotyping useful for the clinical management of patients with atrophic body gastritis? 9 38
18047563 2008
Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. 9 38
18237867 2008
Microevolution of Helicobacter pylori type IV secretion systems in an ulcer disease patient over a ten-year period. 9 38
17942650 2007
Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. 9 38
18004396 2007
Serum ghrelin as a marker of atrophic body gastritis in patients with parietal cell antibodies. 9 38
17711921 2007
Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins. 9 38
17922404 2007
Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. 9 38
17948927 2007

Variations for Gastritis

ClinVar genetic disease variations for Gastritis:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CEL NM_001807.5(CEL): c.1966G> C (p.Ala656Pro) single nucleotide variant Uncertain significance rs587780309 9:135946855-135946855 9:133071468-133071468

Expression for Gastritis

Search GEO for disease gene expression data for Gastritis.

Pathways for Gastritis

Pathways related to Gastritis according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
7 11.84 PTGS2 NOS2 IL1B CXCL8
8 11.83 PTGS2 IL1B CXCL1
9 11.8 IL1B CXCL8 CXCL1
10 11.78 PTGS2 IL1B CXCL8
11 11.77 NOS2 IL1B CXCL8 CXCL1
12 11.73 IL1B CXCL8 CXCL1
13 11.73 PTGS2 NOS2 IL1B CXCL8 CXCL1
14 11.62 NOS2 IL1B CXCL8 CXCL1
15 11.61 NOS2 IL1B CXCL8
16 11.47 IL1B CXCL8 CXCL1
17 11.42 PTGS2 NOS2 CXCL8
Show member pathways
Show member pathways
11.3 PGA5 PGA4 PGA3
21 10.89 PTGS2 CXCL8
23 10.21 HRH2 GAST

GO Terms for Gastritis

Cellular components related to Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 TFF2 S100A8 PGC IL1RN IL1B GHRL
2 extracellular region GO:0005576 9.53 TFF2 S100A8 PGC PGA5 PGA4 PGA3
3 secretory granule lumen GO:0034774 9.5 S100A8 GHRL DEFA5
4 Golgi lumen GO:0005796 9.43 DEFB4A DEFB1 DEFA5
5 multivesicular body lumen GO:0097486 9.33 PGA5 PGA4 PGA3

Biological processes related to Gastritis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.93 PTGS2 NOS2 IL1RN IL1B CXCL8 CXCL1
2 chemotaxis GO:0006935 9.91 S100A8 DEFB4A DEFB1 CXCL8 CXCL1
3 response to lipopolysaccharide GO:0032496 9.9 S100A8 PTGS2 NOS2 IL1B
4 defense response GO:0006952 9.89 DEFB4A DEFB1 DEFA5 CXCL8 CXCL1
5 defense response to bacterium GO:0042742 9.88 S100A8 NOS2 DEFB4A DEFB1 DEFA5 CHGA
6 defense response to Gram-positive bacterium GO:0050830 9.85 DEFB4A DEFB1 DEFA5 CHGA
7 response to bacterium GO:0009617 9.81 NOS2 DEFB1 ADH7
8 chemokine-mediated signaling pathway GO:0070098 9.79 TFF2 CXCL8 CXCL1
9 killing of cells of other organism GO:0031640 9.75 DEFB4A DEFA5 CHGA
10 defense response to fungus GO:0050832 9.74 S100A8 DEFA5 CHGA
11 innate immune response in mucosa GO:0002227 9.73 NOS2 DEFB1 DEFA5
12 protein catabolic process GO:0030163 9.73 PGC PGA5 PGA4 PGA3
13 defense response to Gram-negative bacterium GO:0050829 9.72 NOS2 DEFB4A DEFB1 DEFA5 CHGA
14 digestion GO:0007586 9.67 PGC PGA5 PGA4 PGA3
15 neutrophil chemotaxis GO:0030593 9.65 S100A8 IL1RN IL1B CXCL8 CXCL1
16 response to ethanol GO:0045471 9.64 S100A8 ADH7
17 cellular response to lipopolysaccharide GO:0071222 9.63 NOS2 IL1RN IL1B DEFA5 CXCL8 CXCL1
18 negative regulation of blood vessel diameter GO:0097756 9.62 PTGS2 CHGA
19 response to glucocorticoid GO:0051384 9.61 PTGS2 IL1RN
20 positive regulation of fever generation GO:0031622 9.59 PTGS2 IL1B
21 peptidyl-cysteine S-nitrosylation GO:0018119 9.58 S100A8 NOS2
22 memory GO:0007613 9.54 PTGS2 HRH2
23 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.35 DEFB4A DEFB1 DEFA5 CXCL8 CXCL1
24 ovulation GO:0030728 9.33 PTGS2
25 antimicrobial humoral response GO:0019730 9.02 S100A8 DEFB4A DEFB1 DEFA5 CHGA
26 G protein-coupled receptor signaling pathway GO:0007186 10.15 HRH2 GHRL GAST DEFB4A DEFB1 CXCL8
27 immune response GO:0006955 10.02 IL1RN IL1B HRH2 DEFB4A DEFB1 CXCL8
28 inflammatory response GO:0006954 10 S100A8 PTGS2 IL1RN IL1B CXCL8 CXCL1

Molecular functions related to Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 IL1RN IL1B CXCL8 CXCL1
2 interleukin-1 receptor binding GO:0005149 9.26 IL1RN IL1B
3 CCR6 chemokine receptor binding GO:0031731 8.96 DEFB4A DEFB1
4 aspartic-type endopeptidase activity GO:0004190 8.92 PGC PGA5 PGA4 PGA3

Sources for Gastritis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....